EXPERT FORUM INVITATION

Rethinking approaches to B-cell malignancies

To register please contact:

Hilleke Doon email: hilleke.doon@gilead.com tel: 020 - 718 36 50

Veronique Alberdingk Thijm email: veronique.alberdingkthijm@gilead.com tel: 020 - 718 36 50



This meeting is organised and funded by Gilead Sciences Europe Ltd.

Gilead Sciences Netherlands B.V. Claude Debussylaan 22 1082 MD Amsterdam www.gilead.com

ZDG/NL/16-11/2035

JOIN US AT THE HILTON LONDON METROPOLE LONDON, UK 10-11 MARCH 2017



This meeting will provide an opportunity for experts in the field of haematology to learn about advances in the treatment of chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL). The Expert Forum will be of high scientific value and incorporate interactive case study workshops.

	Meeting Chairs:	
	Michele Ghielmini,	Véronique Leblond, Davia, France.
	Bellinzona, Switzerland	Paris, France
5	Confirmed Faculty includes:	
	• Hinrich Abken,	• Klaus Okkenhaug,
1	Cologne, Germany	Cambridge, UK
	Antonio Cuneo,	• Piers Patten,
	Ferrara, Italy	London, UK
	Pierre Feugier,	 María José Terol,
	Nancy, France	Valencia, Spain
	• Rüdiger Liersch,	 Clemens-Martin Wendtner,
	Münster, Germany	Munich, Germany
	• Martin Müller,	• Andrew Zelenetz,
	Tübingen, Germany	New York, US
	• Talha Munir,	• Pier Luigi Zinzani,
	Leeds, UK	Bologna, Italy

Agenda

Friday 10 March, 2017				
Time	Торіс			
14:00-14:30	Coffee on arrival			
14:30-14:35	Chairs' welcome			
14:35-15:05	Evolution of treatment for B-cell maligna			
15:05-15:25	PI3K inhibition in FL and CLL: Insights fro			
15:25-15:45	Current treatments in refractory FL			
15:45-16:10	Current treatments in high-risk and relaps			
16:10-16:40	Coffee break			
16:40-17:00	Practical management of FL and CLL pat			
17:00-17:20	Panel discussion			
17:20-17:30	Closing remarks			

Saturday 11 March, 2017			
	Time	Торіс	
	08:55-09:00	Chair's welcome to Day 2	
	09:00-09:45	Precision therapy: Engineering the future Scientific perspectives Clinical perspectives	
	09:45-09:55	Q&A	
	09:55-10:00	Introduction to workshops	
	10:00-10.30	Coffee break	
	10:30-12:00	Workshop 1: Identifying appropriate patients for idelali	
	12:00-13:00	Lunch	
	13:00-14:30	Workshop 2: Collaborative approaches to idelalisib pat	
	14:40-15:00	Workshop feedback and panel discussion	
	15:00-15:15	Meeting summary and close	

ancies: A personal journey rom the lab and the clinic

osed CLL

atients in the era of targeted therapy

of B-cell malignancy treatment

lisib treatment

tient management